Clinical Trial Update: Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing irinotecan/capecitabine versus capecitabine in HER2-negative metastatic breast cancer. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Metastatic Breast Cancer | Phase 3 | Status: UNKNOWN